Merck, Sharp & Dohme Corp., Kenilworth, New Jersey, was awarded a $1,207,999,848 firm-fixed-price contract for 1,696,629 treatment courses of the oral antiviral MK-4482. Bids were solicited via the internet with one received. Work will be performed in Kenilworth, New Jersey, with an estimated completion date of June 15, 2022. Fiscal 2020 Coronavirus Aid, Relief and Economic Security (CARES) Act funds in the amount of $1,207,999,848 were obligated at the time of the award. U.S. Army Contracting Command, Aberdeen Proving Ground, Maryland, is the contracting activity (W911QY-21-C-0031). (Awarded June 7, 2021)
Contract Award: Merck Sharp & Dohme Corp. (Kenilworth, New Jersey) – $1,207,999,848
Defense Daily Staff
SHARE:
